Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K16/10 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/239949HUMAN RECOMBINANT MONOCLONAL ANTIBODY AGAINST SARS-COV-2 SPIKE GLYCOPROTEIN
WO 02.12.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/EP2021/064352 Applicant DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E. V. (DZNE) Inventor KREYE, Jakob
The disclosure relates to a human recombinant monoclonal antibody or antibody fragment that binds the receptor binding domain (RBD) of the S1 subunit (S1) of a Spike glycoprotein of SARS-CoV-2, wherein the heavy and light chain variable amino acid sequences of the antibody (VH and VL) were isolated from convalescent COVID-19 patients. In further aspects, the disclosure relates to a nucleic acid molecule encoding an antibody or antibody fragment of the disclosure, a host cell comprising the nucleic acid molecule, and a pharmaceutical composition comprising an antibody or antibody fragment of the disclosure. The disclosure further relates to corresponding medical uses and therapeutic methods of administering an antibody or antibody fragment of the disclosure in the treatment and/or prevention of a medical condition associated with a SARS Coronavirus, in addition to diagnostic uses and methods.
2.WO/2021/247925STRUCTURE-GUIDED IMMUNOTHERAPY AGAINST SARS-COV-2
WO 09.12.2021
Int.Class A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Appl.No PCT/US2021/035782 Applicant VIR BIOTECHNOLOGY, INC. Inventor CORTI, Davide
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind in certain regions of a SARS-CoV-2 S glycoprotein and can neutralize a SARS-CoV-2 infection. Also provided are immunogenic compositions that comprise a SARS-CoV-2 S glycoprotein or a portion thereof that is capable of being bound by an antibody or antigen-binding fragment.
3.WO/2022/027088LATERAL FLOW DEVICE AND USES THEREOF
WO 10.02.2022
Int.Class G01N 33/543
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
Appl.No PCT/AU2021/050839 Applicant THE UNIVERSITY OF MELBOURNE Inventor GODFREY, Dale
The present disclosure provides a lateral flow assay (LFA) device for detecting neutralising antibodies against SARS-CoV-2 in a biological fluid sample, and uses thereof. The assay uses competition of the neutralising antibodies present in the sample with the ACE2-RBD on the test strip, leading to binding inhibition and decrease in signal intensity in the test region.
4.WO/2022/067269ANTIBODIES AGAINST SARS-COV-2
WO 31.03.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2021/052481 Applicant HUMABS BIOMED SA Inventor CORTI, Davide
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. In certain embodiments, an antibody or antigen-binding fragment is capable of binding to a SARS-CoV-2 spike protein in the N-terminal domain (NTD). Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors that comprise a polynucleotide, host cells that express an antibody or antigen-binding fragment, pharmaceutical compositions, and methods for treating or diagnosing a SARS-CoV-2 infection.
5.20210388067COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOF
US 16.12.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 17405650 Applicant Adagio Therapeutics, Inc. Inventor Laura Walker

The present disclosure is directed to antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) and/or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies and antibodies that bind to and/or compete for binding to the same linear or conformational epitope(s) on CoV-S. Further disclosed are conjugates of anti-CoV-S antibodies, and binding fragments thereof, conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the disclosure include the use of anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses, or the S protein thereof, and conditions where neutralization or inhibition of coronaviruses, or the S protein thereof, would be therapeutically and/or prophylactically beneficial.

6.WO/2021/203034ALIMENTARY AND SYSTEMIC ANTIVIRAL THERAPEUTICS
WO 07.10.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2021/025630 Applicant FIREBREAK, INC. Inventor STARZL, Timothy, W.
Methods and compositions are provided for rapid preparation of anti-SARS- CoV-2 protein polyclonal IgY antibodies. Compositions comprising the antibodies are useful for decreasing transmission, duration, and/or severity of coronavirus disease 2019 (COVID-19). Lingual and sublingual alimentary traps, oral, parenteral, and inhalable compositions are provided for preventing and treating COVID-19. The compositions can be rapidly tailored for seasonal or even monthly mutations in the SARS-CoV-2 viral antigenic proteins. Improved methods of generating IgY antibodies are also provided.
7.20210347858ALIMENTARY AND SYSTEMIC ANTIVIRAL THERAPEUTICS
US 11.11.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 17221515 Applicant Firebreak, Inc. Inventor Timothy W. Starzl

Methods and compositions are provided for rapid preparation of anti-SARS-CoV-2 protein polyclonal IgY antibodies. Compositions comprising the antibodies are useful for decreasing transmission, duration, and/or severity of coronavirus disease 2019 (COVID-19). Lingual and sublingual alimentary traps, oral, parenteral, and inhalable compositions are provided for preventing and treating COVID-19. The compositions can be rapidly tailored for seasonal or even monthly mutations in the SARS-CoV-2 viral antigenic proteins. Improved methods of generating IgY antibodies are also provided.

8.WO/2022/040423CORONAVIRUS NANOBODIES AND METHODS FOR THEIR USE AND IDENTIFICATION
WO 24.02.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2021/046685 Applicant UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION Inventor SHI, Yi
Disclosed herein are coronavirus neutralizing antibodies and uses thereof for treating and preventing a coronavirus infection in a subject.
9.WO/2021/211775ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF USING THE SAME
WO 21.10.2021
Int.Class A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Appl.No PCT/US2021/027375 Applicant VIR BIOTECHNOLOGY, INC. Inventor CORTI, Davide
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. In certain embodiments, the presently disclosed antibodies are capable of binding to S proteins of multiple sarbecoviruses and/or neutralizing infection by multiple sarbecoviruses. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a sarbecovirus infection, such as a SARS-CoV-2 infection.
10.WO/2022/094622POLYPEPTIDES FOR DETECTION AND TREATMENT OF SARS-COV-2
WO 05.05.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2021/072152 Applicant THE UNIVERSITY OF CHICAGO Inventor KOSSIAKOFF, Anthony
Aspects of the present disclosure relate to polypeptides that specifically bind to a SARS-CoV-2 spike protein, and to methods of use for treatment, prevention, and diagnosis of a SARS-CoV-2 infection. Certain aspects are directed to antibodies and fragments thereof, including Fabs, configured to bind to various epitopes within the receptor binding domain (RBD) of a SARS-CoV-2 spike protein. Compositions, kits, and methods for detection of SARS-CoV-2 are also disclosed.